This systematic review (SR) aimed to evaluate the comparative effectiveness and harms of medical therapies for non-metastatic, locally advanced gastric adenocarcinoma to inform the development of an American Society of Clinical Oncology (ASCO) Clinical Practice Guideline. Specifically, the SR addressed (1) the comparative effectiveness and harms of chemotherapy, radiation therapy, targeted therapy, and immunotherapy, including their sequences and combinations, and whether treatment effectiveness and harms vary based on (2) tumor characteristics or (3) patient subpopulations.
